StockData
Harvard Apparatus Regenerative Technology, Inc. logo

Harvard Apparatus Regenerative Technology, Inc. (HRGN) company profile

HRGNOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30
$2.21−0.02 (-0.72%)

Close on Oct 19, 2026Market cap $38.92MP/E –Yield –

About Harvard Apparatus Regenerative Technology

Surgical & Medical Instruments & Apparatus, SIC 3841

Harvard Apparatus Regenerative Technology, Inc. is a clinical-stage biotechnology company developing regenerative medicine therapies for disorders of the gastrointestinal system and other organs. The company operates two segments: Regenerative Biotech and Consumer Health Products. Its regenerative platform uses patient-derived stem cells seeded on temporary synthetic scaffolds to restore organs damaged by cancer, trauma, or congenital defects, with lead product candidates targeting esophageal reconstruction, colon repair, and pediatric esophageal atresia. Through its Hong Kong subsidiary, the company also markets consumer health items and dietary supplements directly to consumers via eCommerce.

The company is headquartered in Holliston, Massachusetts, where it manufactures bioreactors and scaffolds in clean-room facilities. Cell seeding operations take place at an FDA-approved facility at the University of Texas Medical Branch. The business conducts clinical trials across three activated medical centers in the United States and collaborates on research initiatives with institutions in Massachusetts, Connecticut, and Beijing, China. Its consumer health operations primarily target customers in Asia.

Summary of the business section of Harvard Apparatus Regenerative Technology's latest annual report, written by StockData.

Company profile

Company

Legal name
Harvard Apparatus Regenerative Technology, Inc.
Founded
2012
Headquarters
Holliston, MA
Address
84 October Hill Road, Suite 11 01746
Phone
(774) 233-7300
Website
hregen.com
Employees
8, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
CBIZ CPAs P.C., Boston, MA

Stock & identifiers

Ticker
HRGN
Former tickers
BSTG until Jul 20, 2023; HART until May 12, 2016
Exchange
OTC
IPO date
Oct 21, 2013
Shares outstanding
18M, Aug 10, 2026
Public float
$15.60M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-20 reverse, Dec 22, 2017
SEC CIK
1563665
FIGI
BBG003Q1GHB5
Share class FIGI
BBG003Q1GJ21
EIN
45-5210462

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Junli HeCEO, Director1,332,930
David GreenDirector175,329
Ronald J. PackardDirector–
James E. ShmerlingDirector23,756
Jing ChenDirector210,000
Ting LiDirector–
Herman SanchezDirector–
Mao ZhangDirector2,113,784

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$439.97K$365.05K$208.70K$33–
FY2024$1.28M$894.53K$246.34K$54–
FY2023$5.79M$5.79M$233.39K$91–
FY2022$37.15K-$10$227.53K$274–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOtherTotalvs. prior year
Junli (Jerry) He
Chief Executive Officer
$423.08K$16.89K$439.97K-66%
Hong Yu
President
$177.69K$9.96K$187.65K-15%
William Fodor
Chief Scientific Officer
$198.85K$11.66K$210.51K-15%
Joseph Damasio
Chief Financial Officer
$215.77K$12.18K$227.95K-15%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, our consolidated business employed 8 individuals.”

Corporate history

Events identified from SEC filings

DateEventDetails
Apr 14, 2025Auditor changeChange in certifying accountant (8-K Item 4.01)
Jul 10, 2023Name changeName changed from Biostage, Inc. to Harvard Apparatus Regenerative Technology, Inc.
Oct 12, 2022Auditor changeChange in certifying accountant (8-K Item 4.01)
Jul 9, 2021Auditor changeChange in certifying accountant (8-K Item 4.01)
May 27, 2021Auditor changeChange in certifying accountant (8-K Item 4.01)
May 17, 2021Late filingNotification of late filing
Mar 31, 2021Late filingNotification of late filing
Jul 10, 2018Auditor changeChange in certifying accountant (8-K Item 4.01)
Apr 6, 2018Auditor changeChange in certifying accountant (8-K Item 4.01)
Dec 7, 2017Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 7, 2017DelistingNotice of delisting from exchange (Form 25)
Nov 14, 2017Late filingNotification of late filing
Oct 6, 2017Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 22, 2017Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 22, 2016Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 10, 2015Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 17, 2015Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 31, 2013ListingRegistration of securities on an exchange (Form 8-A)
Jul 31, 2013Spin-offRegistration as a new public company (Form 10), e.g. spin-off
Apr 1, 2013ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?